Welcome, Guest. Please login or register.
December 03, 2021, 05:34:13 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 762692
  • Total Topics: 64802
  • Online Today: 151
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 4
Guests: 121
Total: 125

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Dolutegravir Trumps Other HIV Meds in Cutting Viral Load  (Read 476 times)

0 Members and 1 Guest are viewing this topic.

Online Jim Allen

  • Administrator
  • Member
  • Posts: 18,015
  • Twitter @JimAllenDublin
    • HIV Lessons
Dolutegravir Trumps Other HIV Meds in Cutting Viral Load
« on: October 18, 2021, 07:55:40 pm »
Not really an unexpected result but found it an interesting read.

Full POZ.com writeup: https://www.poz.com/article/dolutegravir-trumps-hiv-meds-cutting-viral-loadeven-missed-doses

In short:

Quote
DOLUTECAPS study recruited 399 people living with HIV on antiretroviral treatment in France and Switzerland. The participants stayed on their current ARV regimen and were tracked for six months using electronic drug monitoring systems that alerted researchers when they took their pills.

Of the nearly 400 participants, 102 were on a dolutegravir-containing regimen; 90 were on a raltegravir-based regimen, 100 were taking non-nucleoside reverse transcriptase inhibitor (NNRTI) and 107 were on a boosted protease inhibitor.

The dolutegravir recipients were divided into three groups, chosen in part because of difficulty remembering to take their regimen every day.

At six months, 17% of people on a dolutegravir regimen still had a detectable viral load compared with 20% of people taking raltegravir, 12% of those taking a NNRTI and 24% of those taking a boosted protease inhibitor.

However, no one on dolutegravir with detectable HIV showed evidence of mutations conferring resistant to integrase inhibitors, the class of drugs to which dolutegravir belongs. Meanwhile, four of the 18 people taking raltegravir, an older integrase inhibitor, showed evidence of resistance.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Offline CircularNatural

  • Member
  • Posts: 29
  • 🇦🇷 Joined Sept 2021
Re: Dolutegravir Trumps Other HIV Meds in Cutting Viral Load
« Reply #1 on: October 19, 2021, 02:11:48 pm »
 ;D ;D ;D ;D ;D ;D ;D ;D ;D
🇦🇷 "Hope is the only thing stronger than fear."

Offline Bucklandbury

  • Member
  • Posts: 125
Re: Dolutegravir Trumps Other HIV Meds in Cutting Viral Load
« Reply #2 on: October 20, 2021, 05:18:23 pm »
Presumably bictegravir, which is structurally derived from dolutegravir, is equally good, but I realize the study didn't study that Gilead molecule.

https://www.gilead.com/news-and-press/press-room/press-releases/2021/7/four-year-biktarvy-data-presented-at-ias-2021-demonstrate-high-efficacy-and-durable-viral-suppression-in-treatment-nave-adults

 


Terms of Membership for these forums
 

© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.